>STARTSEITE

PBR Nachrichten

PBR (Pharmaceutical Business Review) ist ein Onlineportal mit News zur Pharma- und Biotechnologiebranche. Die Redaktion berichtet über neue Medikamente und deren Zulassungsverfahren, sowie über geschäftliche Entwicklungen von Pharmaunternehmen.
 
18.04.19 - 13:25
CASI Pharmaceuticals in-licenses rights to novel anti-CD38 monoclonal antibody program from Black Belt Therapeutics (PBR)
 
Under the terms of the agreement, CASI has obtained global rights to TSK011010 for an upfront payment of 5 million euros and an equity investment of 2 million The post CASI Pharmaceuticals in-licenses rights to novel anti-CD38 monoclonal antibody pr...
18.04.19 - 13:13
SK Biopharmaceuticals, twoXAR collaborate to develop treatments for NSCLC (PBR)
 
As per terms of the deal, twoXAR will apply its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms The post SK Biopharmaceuticals, twoXAR collaborate to develop treatments for NSC...
18.04.19 - 13:13
FDA approves DUAKLIR PRESSAIR to treat chronic obstructive pulmonary disease (PBR)
 
DUAKLIR PRESSAIR is a fixed-dose LAMA/LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium and the long-acting beta agonist (LABA) formoterol. It is administered twice daily via the The post FDA approves DUAKLIR PRESSAIR to tr...
18.04.19 - 09:49
LabCorp to buy Envigo′s non-clinical research services business in $485m deal (PBR)
 
LabCorp said that the proposed deals will make the company to pay a net cash of $485m and will add an incremental $156m to revenues on a pro The post LabCorp to buy Envigo's non-clinical research services business in $485m deal appeared first on Ph...
17.04.19 - 13:37
DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases (PBR)
 
The research collaboration is part of Atomwise's Artificial Intelligence Molecular Screen (AIMS) Awards program. The Centers for Disease Control and Prevention (CDC) estimates that 6-7 million people in The post DNDi, Atomwise collaborate to advanc...
17.04.19 - 13:37
FDA grants orphan drug designation to NeoImmuneTech′s Hyleukin-7 for idiopathic CD4+ lymphocytopenia treatment (PBR)
 
Hyleukin-7 also received ODD from the European Medicines Agency in 2017, and it is the first and only agent that has obtained ODD for ICL. ICL was first The post FDA grants orphan drug designation to NeoImmuneTech's Hyleukin-7 for idiopathic CD4+ l...
17.04.19 - 13:25
MS Pharma to acquire European pharmaceutical firm Genepharm (PBR)
 
Based in Athens of Greece, Genepharm is involved in the development, manufacturing and out-licensing of high-value generic pharmaceutical products. The company, which owns a wide portfolio of products, The post MS Pharma to acquire European pharmace...
17.04.19 - 10:02
Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis (PBR)
 
Under the three-year deal, the partnership will use insitro's platform to create disease models for NASH and discover targets that can impact clinical progression and regression of the The post Gilead, insitro collaborate to develop therapies for n...
17.04.19 - 09:13
FDA accepts Novartis’s BLA for brolucizumab for treatment of wet AMD (PBR)
 
The company said that it used a priority review voucher to fast track the review of the regulator on brolucizumab in order to make it available to patients The post FDA accepts Novartis’s BLA for brolucizumab for treatment of wet AMD appeared ...
16.04.19 - 11:02
Allele, SCM Lifescience sign joint research and development agreement to develop iPSC-based diabetes treatment (PBR)
 
iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology, The post Allele, SCM Lifescience sign joint research and deve...
16.04.19 - 10:49
Alnylam initiates ILLUMINATE-B phase 3 pediatric study of Lumasiran to treat primary hyperoxaluria type 1 (PBR)
 
The study will enroll approximately eight patients with PH1 under six years of age. The primary endpoint is the percent reduction in urinary oxalate from baseline to six The post Alnylam initiates ILLUMINATE-B phase 3 pediatric study of Lumasiran to...
16.04.19 - 09:48
Catalent to buy CDMO Paragon Bioservices for $1.2bn (PBR)
 
Paragon Bioservices is a major viral vector development and manufacturing partner for gene therapies. Paragon president and CEO Pete Buzy said: "We are excited to join forces with The post Catalent to buy CDMO Paragon Bioservices for $1.2bn appeared...
15.04.19 - 12:25
Dr. Reddy’s Laboratories announces acquisition of ANDA portfolio (PBR)
 
The portfolio includes more than 30 generic injectable products. These products will require to be technology transferred and could be launched within the next one to two years. The post Dr. Reddy’s Laboratories announces acquisition of ANDA p...
15.04.19 - 12:25
Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH (PBR)
 
The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of The post Gilead Sciences and Nov...
15.04.19 - 12:01
AAV gene therapy company AskBio secures $235m investment (PBR)
 
The investment in AskBio includes an amount of $225m committed by global alternative asset firm TPG Capital and life sciences investment firm Vida Ventures in exchange of a The post AAV gene therapy company AskBio secures $235m investment appeared f...
15.04.19 - 10:01
Janssen′s Balversa gets FDA approval for metastatic bladder cancer (PBR)
 
Balversa is now indicated in the US for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration The post Janssen's Balversa gets FDA approval for metastatic bladder canc...
12.04.19 - 12:49
Wockhardt receives US FDA approval for cancer drug (PBR)
 
Wockhardt's Decitabine Injection is a generic version of Dacogen, marketed in USA and other countries by Otsuka. Decitabine is used to treat Myelodysplastic syndromes (MDS), a group of The post Wockhardt receives US FDA approval for cancer drug app...
12.04.19 - 12:49
Moleculin announces agreement with Emory University to conduct pediatric brain tumor trial (PBR)
 
The study will be conducted at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta. “Given the exciting data Emory University researchers presented at the The post Moleculin announces agreement with Emory Univer...
12.04.19 - 09:25
Janssen’s HIV drug SYMTUZA yields positive results in DIAMOND trial (PBR)
 
The trial, called DIAMOND, is the first prospective phase 3 trial which is assessing the rapid initiation of a single-tablet regimen (STR) SYMTUZA for the treatment of human The post Janssen’s HIV drug SYMTUZA yields positive results in DIAMON...
11.04.19 - 04:01
Lynparza secures European approval for type of advanced breast cancer (PBR)
 
The latest approval for Lynparza in Europe is for its use as a monotherapy for adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor The post Lynparza secures European approval for type of advanced breas...
>Zitat des Tages: Die Erde bringt alle Dinge hervor und nimmt alle wieder zu sich. - Sprichwort Großbritannien
Partner:    >Tradegate Börse | >DB Xmarkets | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ Boersentreff.de - Die Märkte im Blick!